Trade Names:Brethine- Tablets 2.5 mg- Tablets 5 mg- Injection 1 mg/mLBricanyl Turbuhaler (Canada)
Produces bronchodilation by relaxing bronchial smooth muscle through beta 2 -receptor stimulation.
Terbutaline C max is approximately 8.5 ng/mL; T max is about 1 to 3 h, and AUC is approximately 54 h•ng/mL. Terbutaline bioavailability is 103%.
The sulfate conjugate is the major metabolite.
Terbutaline t ½ is about 3.4 h. Approximately 90% is excreted in urine at 96 h after subcutaneous administration, with about 60% being unchanged drug. Urinary excretion is the primary route of elimination.
Onset of action is 30 min.
Time to peak effect of terbutaline is 120 to 180 min.
Duration of action is 4 h or longer.
Treatment of reversible bronchospasm associated with asthma, bronchitis, and emphysema.
Cardiac arrhythmias associated with tachycardia.
PO 2.5 to 5 mg at 6 h intervals, 3 times daily during waking hours. Do not exceed 15 mg in 24 h.Children 12 to 15 yr of age
PO 2.5 mg 3 times daily. Do not exceed 7.5 mg in 24 h. Subcutaneous 0.25 mg given in lateral deltoid area. May repeat in 15 to 30 min. Do not exceed 0.5 mg in 4 h.
Store at room temperature. Protect from light.
Block bronchodilator effect of terbutaline.MAOIs
Hypertension may occur.Tricyclic antidepressants
CV effects of terbutaline may be enhanced.
None well documented.
Palpitations; tachycardia; chest discomfort or pain; arrhythmias; BP changes/hypertension.
Stimulation; tremor; dizziness; nervousness; drowsiness; headache; weakness.
Nausea; vomiting; GI distress.
Elevated liver enzymes.
Hypokalemia (with high doses).
Flushing; sweating; muscle cramps; hypersensitivity vasculitis; ECG changes (eg, sinus pause, atrial premature beats, AV block, ventricular premature beats, ST-T-wave depression, T-wave inversion, sinus bradycardia, atrial escape beat with aberrant conduction); increased heart rate; muscle cramps; central stimulations; pain at injection site; elevations in liver enzymes; seizures; hypersensitivity vasculitis.
Category B .
Excreted in breast milk.
Safety and efficacy in children younger than 12 yr of age not established.
Lower doses may be required.
May inhibit uterine contractions and delay preterm labor.
Hypersensitivity (allergic) reactions can occur after administration.
A significant increase in the incidence of leiomyomas of the mesovarium and ovarian cysts has been demonstrated.
Toxic symptoms in patients with CV disorders may occur.
CNS stimulation may occur; use cautiously in patients with history of seizures or hyperthyroidism.
Dosage adjustment of insulin or oral hypoglycemic agent may be required.
Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use.
Decreases in potassium levels have occurred.
If previously effective dose fails to provide relief, therapy may need to be reassessed.
Tremor, palpitations, increased heart rate, decreased BP, seizures, hypokalemia, muscle cramps, headache, hyperglycemia.
Copyright © 2009 Wolters Kluwer Health.